Display options
Cite
Santoni M, Massari F, Grande E, et al. Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study. Target Oncol. 2021;16(5):625-632doi: 10.1007/s11523-021-00828-z.
Santoni, M., Massari, F., Grande, E., Procopio, G., Matrana, M. R., Rizzo, M., De Giorgi, U., Basso, U., Milella, M., Iacovelli, R., Aurilio, G., Incorvaia, L., Buti, S., Caffo, O., Fornarini, G., Carrozza, F., Mollica, V., Rizzo, A., Farag, F., Molina-Cerrillo, J., & Battelli, N. (2021). Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study. Targeted oncology, 16(5), 625-632. https://doi.org/10.1007/s11523-021-00828-z
Santoni, Matteo, et al. "Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study." Targeted oncology vol. 16,5 (2021): 625-632. doi: https://doi.org/10.1007/s11523-021-00828-z
Santoni M, Massari F, Grande E, Procopio G, Matrana MR, Rizzo M, De Giorgi U, Basso U, Milella M, Iacovelli R, Aurilio G, Incorvaia L, Buti S, Caffo O, Fornarini G, Carrozza F, Mollica V, Rizzo A, Farag F, Molina-Cerrillo J, Battelli N. Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study. Target Oncol. 2021 Sep;16(5):625-632. doi: 10.1007/s11523-021-00828-z. Epub 2021 Aug 02. PMID: 34338966.
Copy Download .nbib Format: NLM
Share it on

Target Oncol. 2021 Sep;16(5):625-632. doi: 10.1007/s11523-021-00828-z. Epub 2021 Aug 02.

Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study.

Targeted oncology

Matteo Santoni, Francesco Massari, Enrique Grande, Giuseppe Procopio, Marc R Matrana, Mimma Rizzo, Ugo De Giorgi, Umberto Basso, Michele Milella, Roberto Iacovelli, Gaetano Aurilio, Lorena Incorvaia, Sebastiano Buti, Orazio Caffo, Giuseppe Fornarini, Francesco Carrozza, Veronica Mollica, Alessandro Rizzo, Fady Farag, Javier Molina-Cerrillo, Nicola Battelli

Affiliations

  1. Oncology Unit, Macerata Hospital, Macerata, Italy. [email protected].
  2. Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  3. Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain.
  4. Department of Medical Oncology, Istituto Nazionale dei Tumori IRCCS, Milan, Italy.
  5. Department of Internal Medicine, Hematology/Oncology, Ochsner Medical Center, New Orleans, LA, USA.
  6. Medical Oncology, I.R.C.C.S. San Matteo University Hospital Foundation, Pavia, Italy.
  7. Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
  8. Department of Medical Oncology, Istituto Oncologico Veneto (IOV) IRCCS, Padua, Italy.
  9. U.O.C. Oncology, Azienda Ospedaliera Universitaria Integrata, University and Hospital Trust of Verona, Verona, Italy.
  10. Medical Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
  11. Medical Oncology Division of Urogenital and Head and Neck Tumours, IEO, European Institute of Oncology IRCCS, Milan, Italy.
  12. Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy.
  13. Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
  14. Medical Oncology Department, Santa Chiara Hospital, Trento, Italy.
  15. Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
  16. Oncology Unit, City Hospital, Faenza, Italy.
  17. Department of MedicalOncology, Hospital Ramón y Cajal, Madrid, Spain.
  18. Oncology Unit, Macerata Hospital, Macerata, Italy.

PMID: 34338966 DOI: 10.1007/s11523-021-00828-z

Abstract

BACKGROUND: Renal cell carcinoma with sarcomatoid differentiation is a highly aggressive form of kidney cancer.

OBJECTIVE: We aimed to analyze the outcomes of patients treated with cabozantinib for metastatic renal cell carcinoma with sarcomatoid features.

METHODS: We retrospectively collected data from 16 worldwide centers. Overall survival and progression-free survival were analyzed using Kaplan-Meier curves. Cox proportional models were used for univariate and multivariate analyses.

RESULTS: We collected data from 66 patients with metastatic sarcomatoid renal cell carcinoma receiving cabozantinib as second-line (51%) or third-line (49%) therapy. The median progression-free survival from the start of cabozantinib was 7.59 months (95% confidence interval [CI] 5.75-17.49) and was longer in male patients (8.81 vs 5.95 months, p = 0.042) and in patients without bone metastases (7.59 vs 5.11 months, p = 0.010); the median overall survival was 9.11 months (95% CI 7.13-23.80). At the multivariate analysis, female sex (hazard ratio = 1.81; 95% CI 1.02-3.37, p = 0.046), bone metastases (hazard ratio = 2.62; 95% CI 1.34-5.10, p = 0.005), and International Metastatic Renal Cell Carcinoma Database Consortium criteria (hazard ratio = 3.04; 95% CI 1.54-5.99, p = 0.001) were significant predictors of worse overall survival.

CONCLUSIONS: Our data show that cabozantinib is active in pretreated patients with sarcomatoid renal cell carcinoma. Biomarkers are needed in this field to select patients for multi-kinase inhibitors or other options.

© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

References

  1. American Cancer Society. Cancer facts and statistics. http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2020 . Accessed 16 Jan 2021. - PubMed
  2. Santoni M, Piva F, Porta C, Bracarda S, Heng DY, Matrana MR, et al. Artificial neural networks as a way to predict future kidney cancer incidence in the United States. Clin Genitourin Cancer. 2021;19(2):e84-91. - PubMed
  3. Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol. 2016;70:93–105. - PubMed
  4. de Peralta-Venturina M, Moch H, Amin M, Tamboli P, Hailemariam S, Mihatsch M, et al. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol. 2001;25:275–84. - PubMed
  5. Conant JL, Peng Z, Evans MF, Naud S, Cooper K. Sarcomatoid renal cell carcinoma is an example of epithelial-mesenchymal transition. J Clin Pathol. 2011;64:1088–92. - PubMed
  6. Piva F, Giulietti M, Santoni M, Occhipinti G, Scarpelli M, Lopez-Beltran A, et al. Epithelial to mesenchymal transition in renal cell carcinoma: implications for cancer therapy. Mol Diagn Ther. 2016;20:111–7. - PubMed
  7. Montironi R, Santoni M, Scarpelli M, Piva F, Lopez-Beltran A, Cheng L, et al. Re: epithelial-to-mesenchymal transition in renal neoplasms. Eur Urol. 2015;68:736–7. - PubMed
  8. Bakouny Z, Braun DA, Shukla SA, Pan W, Gao X, Hou Y, et al. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nat Commun. 2021;12:808. - PubMed
  9. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277–90. - PubMed
  10. Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1103–15. - PubMed
  11. Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. KEYNOTE-426 Investigators. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1116–27. - PubMed
  12. Blum KA, Gupta S, Tickoo SK, Chan TA, Russo P, Motzer RJ, et al. Sarcomatoid renal cell carcinoma: biology, natural history and management. Nat Rev Urol. 2020;17:659–78. - PubMed
  13. Piva F, Santoni M, Scarpelli M, Briganti A, Lopez-Beltran A, Cheng L, et al. Re: Daniel M. Geynisman. Anti-programmed cell death protein 1 (PD-1) antibody nivolumab leads to a dramatic and rapid response in papillary renal cell carcinoma with sarcomatoid and rhabdoid features. Eur Urol. 2015;68:912–4. - PubMed
  14. Di Nunno V, Cubelli M, Massari F. The role of the MET/AXL pathway as a new target for multikinase inhibitors in renal cell carcinoma. Expert Rev Precis Med Drug Dev. 2017;2:169–75. - PubMed
  15. Santoni M, Heng DY, Bracarda S, Procopio G, Milella M, Porta C, et al. Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: focus on sequences and prognostic factors. Cancers. 2019;12:84. - PubMed
  16. Santoni M, Massari F, Bracarda S, Procopio G, Milella M, De Giorgi U, et al. Body mass index in patients treated with cabozantinib for advanced renal cell carcinoma: a new prognostic factor? Diagnostics. 2021;11:138. - PubMed
  17. Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, et al. RECIST 1.1-update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132–7. - PubMed
  18. Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study. J Clin Oncol. 2019;37(15_Suppl.):4500. - PubMed
  19. Tannir NM, Signoretti S, Choueiri TK, McDermott DF, Motzer RJ, Flaifel A, et al. Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma. Clin Cancer Res. 2021;27:78–86. - PubMed
  20. Motzer RJ, Choueiri TK, Powles T. Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER. J Clin Oncol. 2021;39(9_Suppl.):308. - PubMed
  21. Conforti F, Pala L, Bagnardi V, De Pas T, Martinetti M, Viale G, et al. Cancer immunotherapy efficacy and patients’ sex: a systematic review and meta-analysis. Lancet Oncol. 2018;19:737–46. - PubMed
  22. Escudier B, Powles T, Motzer RJ, Olencki T, Arén Frontera O, Oudard S, et al. Cabozantinib, a new standard of care for patients with advanced renal cell carcinoma and bone metastases? Subgroup analysis of the METEOR trial. J Clin Oncol. 2018;36:765–72. - PubMed
  23. Haider MT, Hunter KD, Robinson SP, Graham TJ, Corey E, Dear TN, et al. Rapid modification of the bone microenvironment following short-term treatment with cabozantinib in vivo. Bone. 2015;81:581–92. - PubMed

Publication Types